Post-acute Infectious Syndrome (PAIS): Clinical Trials

2 not yet recruiting. 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	2	Not yet recruiting 2

Follow Post-acute Infectious Syndrome (PAIS): new trials by email Literature Review of Post-acute Infectious Syndrome (PAIS) trials Research Report on Post-acute Infectious Syndrome (PAIS)

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
CD19-B Cell Depletion in PAIS-ME/CFS Patients Inebilizumab, Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)	Phase 2	Not yet recruiting	Charite University, Berlin, Germany	38	2026-12-01	2026-07-24
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE) Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)	Phase 2	Not yet recruiting	Christiana Franke	138	2026-10-01	2026-07-20

Narrower conditions

Fatigue (2)  ·  Hemophilia B (2)  ·  Post-Acute COVID-19 Syndrome (2)  ·  Cognition Disorders (1)  ·  Fatigue Syndrome, Chronic (1)

Broader conditions

Blood Coagulation Disorders (2)  ·  Blood Coagulation Disorders, Inherited (2)  ·  COVID-19 (2)  ·  Chronic Disease (2)  ·  Coagulation Protein Disorders (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Coronaviridae Infections (2)  ·  Coronavirus Infections (2)  ·  Disease Attributes (2)  ·  Genetic Diseases, Inborn (2)  ·  Genetic Diseases, X-Linked (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Hemorrhagic Disorders (2)  ·  Infections (2)

Interventions

Aripiprazole (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  inebilizumab (1)

Sponsors

Charite University, Berlin, Germany (1)  ·  Christiana Franke (1)

Countries

Germany (2)

Top investigators

Christiana Franke, PD MD (1)  ·  Judith Bellmann-Strobl, MD (1)